ISO.JSE ASP ISOTOPES INC
- Market cap
- ZAR 5.35B
- P/E
- -
- P/B
- 119.60x
- ROE
- -30.6%
- Dividend yield
- -
- Fundamental score
- 1.1/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is ISO.JSE undervalued?
Graham numberThe Graham number of ASP ISOTOPES INC cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ASP ISOTOPES INC fundamental analysis
5 of 21 checks passedROE 0/2
Low return on equity (-30.6%), below 10%.
ROA 0/1
Return on assets (-14.1%) is below the industry median (2.8%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-249.4%) is below the industry median (-4.1%).
Revenue Growth 0/2
Revenue did not grow over the past 3 years or is not reported.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 1/2
Moderate debt to equity (78.8%), up to 100%.
Debt Trend 0/1
Debt to equity history is shorter than 5 years.
Cash Runway 2/2
Cash covers 2.1 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (1.2x) is below the industry median (1.2x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
ASP ISOTOPES INC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ASP ISOTOPES INC
ASP Isotopes Inc., a development stage advanced materials company, engages in the production, distribution, marketing, and sale of isotopes in South Africa,Hong Kong, and United States. It operates in two segments, Nuclear Fuels, and Specialist Isotopes and Related Services. The Nuclear Fuels segment focuses on the research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target e…
Full company profileASP ISOTOPES INC financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ASP ISOTOPES INC annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 433K | 4.14M | 23.8M | 18.6M |
| Gross Profit | 0.00 | 139K | 1.60M | 3.41M | 6.29M |
| Operating Income | -5.10M | -16.0M | -26.4M | -57.2M | -118M |
| EBITDA | -4.95M | -16.1M | -31.6M | -157M | -106M |
| Net Income | -4.95M | -16.3M | -32.3M | -175M | -80.9M |
| EPS | -0.14 | -0.33 | -0.45 | -1.57 | -0.62 |
| Balance Sheet | |||||
| Total Assets | 12.5M | 27.5M | 94.3M | 498M | 572M |
| Total Liabilities | 2.68M | 8.71M | 43.2M | 235M | 297M |
| Shareholders' Equity | 9.82M | 16.3M | 47.9M | 204M | 265M |
| Cash & Short-term Investments | 2.39M | 7.91M | 61.9M | 286M | 220M |
| Cash Flow | |||||
| Operating Cash Flow | -2.94M | -5.41M | -16.7M | -37.8M | -82.2M |
| Capital Expenditure | 4.47M | 2.33M | 11.4M | 9.65M | 20.5M |
| Free Cash Flow | -7.41M | -7.74M | -28.1M | -47.4M | -103M |
| Ratios | |||||
| ROE | -50.4% | -99.9% | -67.5% | -85.8% | -30.6% |
| ROA | -39.6% | -59.1% | -34.3% | -35.2% | -14.1% |
| Net Profit Margin | - | -3,761.0% | -780.3% | -734.2% | -434.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ASP ISOTOPES INC dividends
ASP ISOTOPES INC has not paid dividends in the last 4 fiscal years.
Who owns ASP ISOTOPES INC
- Insiders 10.46%
- Institutions 47.11%
- Public & others 42.43%
- Shares outstanding 153M
- Free float 133M
ASP ISOTOPES INC company profile
- Company name
- ASP ISOTOPES INC
- Ticker
- ISO.JSE
- Exchange
- Johannesburg Exchange
- Sector
- Basic Materials
- Industry
- Specialty Chemicals
- Employees
- 271
- Fiscal year end
- December
- Address
- 2200 Ross Avenue, Dallas, TX, United States, 75201
- Phone
- 214 432 8219
- Website
- aspisotopes.com
About ASP ISOTOPES INC
ASP Isotopes Inc., a development stage advanced materials company, engages in the production, distribution, marketing, and sale of isotopes in South Africa,Hong Kong, and United States. It operates in two segments, Nuclear Fuels, and Specialist Isotopes and Related Services. The Nuclear Fuels segment focuses on the research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its Specialist Isotopes and Related Services segment engages in the research and development of technologies and methods used to separate high-value, low-volume isotopes, such as C-14, Mo-100 and Si-28, for target end markets, including pharmaceuticals and agrochemicals, nuclear medical imaging, and semiconductors; provision of related services; and operation of PET labs. The company offers the Aerodynamic Separation Process (ASP) technology, which separates gas species and isotopes in a volatile state; and the Quantum Enrichment (QE) technology, which separates isotopes. It also produces and commercializes Molybdenum-100, Molybdenum-98, and Ytterbium-176 for the nuclear medical industry. In addition, the company develops Zinc-68, Nickel-64, and Xenon-129/136 for the nuclear medical industry; Lithium-7, Uranium-235, and Chlorine-37 for the energy industry; and Germanium-70/72/74 for semiconductor markets. The company was incorporated in 2021 and is based in Dallas, Texas.
ASP ISOTOPES INC management
9- Mr. Paul Elliot Mann C.F.A.Executive Chairman & CEO · born 1976
- Ms. Heather KiesslingChief Financial Officer · born 1965
- Mr. Robert AinscowChief Operating Officer · born 1977
- Mr. Nicholas Michael MitchellCo-Chief Operating Officer · born 1980
- Dr. Hendrik Strydom B. Sc, M. Sc, Ph.D.Chief Technology Officer · born 1961
- Ms. Shveta Vilas DigheHead of Investor Relations
- Mr. Donald George AinscowEVP, General Counsel & Secretary · born 1981
- Mr. Stefano MaraniPresident of Electronics & Space · born 1978
- Dr. Gerdus Kemp M.D., Ph.D.Medical Director & CEO of Pet Labs